secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0001104659-24-035239
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics reports FY2023 net loss $81.4M; cash $70.6M; DKN-01 data positive
--------------------------------------------------------------------------------

- Net loss $81.4M in FY2023 vs $54.6M in FY2022; R&D expenses $73.2M.
- Cash and equivalents $70.6M at Dec 31, 2023; research incentive receivables $0.8M.
- DeFianCe Part A (CRC): 30% ORR, 93% DCR; median PFS 6.3 months in 2L MSS CRC.
- Completed enrollment (170 pts) in DisTinGuish Part C for gastric/GEJ cancer; data expected mid-2024.
- Randomized Part B of DeFianCe (130 pts) enrolling; 80 enrolled as of Mar 15, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465924035239/0001104659-24-035239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465924035239/tm248524d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-035239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer